Evidence map›Paper›PMID 15860583›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2005

Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists.

Ekambar R Kandimalla, Lakshmi Bhagat, Yukui Li, Dong Yu, Daqing Wang, Yan-Ping Cong, Sam S Song, Jimmy X Tang, Tim Sullivan, Sudhir Agrawal

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 97 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ekambar R KandimallaHybridon, Inc., 345 Vassar Street, Cambridge, MA 02139, USA.
Lakshmi Bhagat
Yukui Li
Dong Yu
Daqing Wang
Yan-Ping Cong
Sam S Song
Jimmy X Tang
Tim Sullivan
Sudhir Agrawal

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bacterial DNA and synthetic oligomers containing CpG dinucleotides activate the immune system through Toll-like receptor (TLR) 9. Here, we compare the immunostimulatory activity of three immunomers with different nucleotide sequences containing a synthetic cytosine-phosphate-2'-deoxy-7-deazaguanosine dinucleotide (CpR), called immunomodulatory oligonucleotides (IMOs), in mouse, human, and monkey systems. IMOs induced IL-12 and IFN-gamma secretion more than a control non-CpG IMO in mice. All three IMOs activated HEK293 cells expressing TLR9 but not TLR3, -7, or -8. IMOs induced human B-cell proliferation and enhanced expression of CD86 and CD69 surface markers on B cells. The three IMOs induced CD86 expression on human plasmacytoid dendritic cells, but only IMOs that contained a 5'-terminal TCR nucleotide sequence induced IFN-alpha secretion. A sequence that forms a duplex structure also was required for IFN-alpha induction in human peripheral blood mononuclear cell cultures. IMOs induced chemokine and cytokine gene expression in human peripheral blood mononuclear cells. In monkeys, all three IMOs induced transient changes in peripheral blood leukocytes and lymphocytes and activated B and T lymphocytes. All three IMOs induced IFN-alpha in vivo in monkeys; the IMO sequence that forms a stable secondary structure induced the highest levels of IFN-alpha. These studies are, to our knowledge, the first comprehensive studies to compare the activity of IMOs containing synthetic stimulatory CpR dinucleotides in mouse, monkey, and human systems. These results suggest that IMOs induce strong and rapid immunostimulation and that the CpR dinucleotide is recognized by TLR9, leading to immune-cell activation and cytokine secretion in vitro and in vivo.

Indexed as

AnimalsAntigens, CDAntigens, Differentiation, T-LymphocyteB7-2 AntigenBase SequenceB-LymphocytesCD69 AntigensCell LineCell ProliferationChemokinesCpG IslandsCytokinesDendritic CellsDeoxyguanosineDNA-Binding ProteinsDose-Response Relationship, Drug7-deaza-2'-deoxyguanosineAntigens, CDAntigens, Differentiation, T-LymphocyteB7-2 AntigenCD69 AntigensCD86 protein, humanCd86 protein, mouseChemokinesCytokinesDeoxyguanosineDNA-Binding ProteinsInterferon-gammaInterleukin-12Lectins, C-TypeMembrane GlycoproteinsNucleotidesOligonucleotidesReceptors, Cell SurfaceRNA, MessengerTLR3 protein, humanTLR9 protein, humanTlr9 protein, mouseToll-Like Receptor 3Toll-Like Receptor 9Toll-Like Receptors

Identifiers

PMID15860583
PMCPMC1100782
OpenAlexW2111819461

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.